GLPwatch
Papers (12034)
Page 183 of 201, ranked by citation count.
- Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.
- Tirzepatide in type 1 diabetes: beyond mere weight loss.
- Response by Wiberg et al to Letter Regarding Article, "Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial".
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
- Correction: Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.
- Reply to "Revisiting Tirzepatide's Body Composition Model: Underestimated Fat-Free Mass Loss and Clinical Implications".
- Revisiting Tirzepatide's Body Composition Model: Underestimated Fat-Free Mass Loss and Clinical Implications.
- Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes.
- Effect of Tirzepatide on Cardiovascular Outcomes.
- Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting.
- Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide.
- Development of novel radioiodinated exendin-4 derivatives targeting GLP-1 receptor for detection of β-cell mass.
- EBM BLS: Tirzepatide Remains Effective for Obesity Treatment and Diabetes Prevention at 3 Years of Follow-up.
- Acute Mesenteric Ischemia as a Severe Complication Associated With Tirzepatide: A Case Report and Safety Alert.
- Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital.
- Pharmacosimilars In Obesity Medicine: Informed Choice, Appropriate Choice.
- Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study.
- Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.
- PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC.
- Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity.
- Combination therapy of GLP-1 analogues and insulin: do the benefits outweigh the costs?
- The systems medicine view of semaglutide: from clinical trials to molecular mechanisms.
- Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study.
- Real-World Evidence of Tirzepatide in Indian Adults With Type 2 Diabetes: Significant Early Glycemic and Cardiometabolic Benefits.
- EFFECTS OF LIRAGLUTIDE ON BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
- Indirect treatment comparisons: Choosing the right tool for the job.
- A Multicentre, Prospective, Non-Interventional Single-Arm Study Investigating the Impact of Once-Daily Oral Semaglutide in a Real-World Adult Population With Type 2 Diabetes in Mexico.
- Exendin-4 enhances GLP-1 signaling and reduces anxiety-like behaviors in male heroin withdrawal mice.
- Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.
- Long-Term Assessment of Weight Loss Medications in a Veteran Population.
- Suspected liraglutide (glucagon-like peptide-1 receptor agonist)-induced hyperthyroidism: A case report.
- [Promising molecules for treatment of hyperglycemia in patients with type 2 diabetes].
- [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
- Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.
- Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses.
- Facial nodules following filler injections after initiating compounded tirzepatide use.
- Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale.
- Repairing effects of liraglutide on spinal cord injury in rats via PI3K/AKT/ENOS signaling pathway.
- Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study.
- Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.
- Potential Drug Interaction Between Liraglutide and Clonazepam: A Case Report.
- GLP-1 and MASH: When weight loss isn't the whole story.
- Changes in eating behavior and diet-related quality of life in individuals treated with tirzepatide for type 2 diabetes.
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE<sup>-/-</sup> mice.
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
- Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review.
- Efficacy and safety of orforglipron in obesity with type 2 diabetes mellitus: a GRADE-assessed meta-analysis of randomized controlled trials.
- Reframing GLP-1 Therapies as Cardiometabolic Health Drugs: Beyond the Race to Weight Loss.
- Real-World Evidence of Long-Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years.
- Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities.
- Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.
- Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.
- Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism.
- The role of GIP in carbohydrate metabolism: Implications in the development of therapies for T2DM, a narrative review.
- [Glucagon-like peptide 1 agonists : the fourth pillar of nephroprotection in type 2 diabetes].
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
- [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
- Glucagon-Like Peptide-1 Agonist vs. Placebo and Pulmonary Decline After Open-Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial.
- Liraglutide versus colesevelam for treating bile acid diarrhoea.
- Management of the T2D Patient With High A1C.